Primary hyperaldosteronism resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:
*Unilateral adrenal hyperplasia
*Unilateral adrenal hyperplasia
==Diagnosis and Treatment==
==Diagnosis and Treatment==
{{familytree/start}}{{familytree | | | | | | | | | A01 | | | | | |A01=Preferred screening population:<br>
{{familytree/start}}{{familytree | | | | | | | | | | | | A01 | | | | | |A01=Preferred screening population:<br>
• Blood pressure > 160 / 100 particularly (< 50 years)<br>
• Blood pressure > 160 / 100 particularly (< 50 years)<br>
• Resistant hypertension or refractory hypertension (use of > 3 anti-hypertensives and poor control of blood pressure)<br>
• Resistant hypertension or refractory hypertension (use of > 3 anti-hypertensives and poor control of blood pressure)<br>
Line 27: Line 27:
• Hypertension with a family history of early-onset hypertension (< 20 years) or cerebrovascular accident at age less than 40 years<br>
• Hypertension with a family history of early-onset hypertension (< 20 years) or cerebrovascular accident at age less than 40 years<br>
• Hypertensive first-degree relatives of patients with PA}}
• Hypertensive first-degree relatives of patients with PA}}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | B01 | | | | | |B01=Plasma Renin Activity/Aldosterone Ratio}}
{{familytree | | | | | | | | | | | | B01 | | | | | |B01=Plasma Renin Activity/Aldosterone Ratio}}
{{familytree | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| }}
{{familytree | | | | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| }}
{{familytree | | C01 | | | | | | | | | | | |C02|C01=Normal or High Renin (Plasma Renin/Aldosterone ratio <10|C02=Suppressed Renin (Plasma Renin/Aldosterone ratio >20}}
{{familytree | | | | | C01 | | | | | | | | | | | |C02|C01=Normal or High Renin (Plasma Renin/Aldosterone ratio <10|C02=Suppressed Renin (Plasma Renin/Aldosterone ratio >20}}
{{familytree | | |!| | | | | | | | | | | | | |!| }}
{{familytree | | | | | |!| | | | | | | | | | | | | |!| }}
{{familytree | | D01 | | | | | | | | | | | |D02|D01=•Renin-secreting tumors<br>•Diuretic use<br>•Renovascular hypertension<br>•Coarctation of aorta<br>•Malignant phase hypertension|D02=Urinary aldosterone}}
{{familytree | | | | | D01 | | | | | | | | | | | |D02|D01=•Renin-secreting tumors<br>•Diuretic use<br>•Renovascular hypertension<br>•Coarctation of aorta<br>•Malignant phase hypertension|D02=Urinary aldosterone}}
{{familytree | | | | | | |,|-|-|-|-|-|-|-|-|-|+|-|-|-|-|.|}}
{{familytree | | | | | | | | | |,|-|-|-|-|-|-|-|-|-|+|-|-|-|-|.|}}
{{familytree | | | | | |E01| | | | | | | |E02| | |E03|E01=Elevated|E02=Normal|E03=Low|}}
{{familytree | | | | | | | | |E01| | | | | | | |E02| | |E03|E01=Elevated|E02=Normal|E03=Low|}}
{{familytree | | | | | | |!| | | | | | | | | |!| | | | |!| }}
{{familytree | | | | | | | | | |!| | | | | | | | | |!| | | | |!| }}
{{familytree | | | | | |F01| | | | | | | |F02| | |F03|F01=Conn's syndrome (Primary aldosteronism)|F02=Profound K+ depletion|F03=• 17 alpha hydroxylase deficiency<br>• 11 beta hydroxylase deficiency<br>• Liddle's syndrome<br>• Licorice ingestion<br> •Deoxycorticosterone producing tumor|}}
{{familytree | | | | | | | | |F01| | | | | | | |F02| | |F03|F01=Conn's syndrome (Primary aldosteronism)|F02=Profound K+ depletion|F03=• 17 alpha hydroxylase deficiency<br>• 11 beta hydroxylase deficiency<br>• Liddle's syndrome<br>• Licorice ingestion<br> •Deoxycorticosterone producing tumor|}}
{{familytree | | | | | | |!| | | | | | | | | | | | | | |!| | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | |!| | | | }}
{{familytree | | | | | |G01| | | | | | | | | | | | |G02|G01=Do confirmatory tests:<br> •Fludrocortisone supression test (Positive test= Aldosterone > 6 ng / dl and simultaneous PRA levels < than 1.0 ng / ml / hour)<br>OR<br> •Intravenous saline load testing (Positive test= Aldosterone more than 10 ng / dl)<br>OR<br> •Oral sodium loading test (Positive test= 24-hour urinary aldosterone excretion > 12 μg / day<br>OR<br> •Captopril challenge test (Positive test= PAC / PRA > 30, measured two hours after the administration of 25 mg or 50 mg of captopril)|G02=Add Mineralocrticoid antagonist for 8 weeks}}
{{familytree | | |boxstyle=text-align: left; | | | | | | |G01| | | | | | | | | | | | |G02|G01=Do confirmatory tests:<br> •Fludrocortisone supression test (Positive test= Aldosterone > 6 ng / dl and simultaneous PRA levels < than 1.0 ng / ml / hour)<br>OR<br> •Intravenous saline load testing (Positive test= Aldosterone more than 10 ng / dl)<br>OR<br> •Oral sodium loading test (Positive test= 24-hour urinary aldosterone excretion > 12 μg / day<br>OR<br> •Captopril challenge test (Positive test= PAC / PRA > 30, measured two hours after the administration of 25 mg or 50 mg of captopril)|G02=Add Mineralocrticoid antagonist for 8 weeks}}
{{familytree | | | | | | |!| | | | | | | | | | | |,|-|-|^|-|-|.}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | |,|-|-|^|-|-|.}}
{{familytree | | | | | | |!| | | | | | | | | | |H01| | | |H02|H01=BP response|H02=No BP response}}
{{familytree | | | | | | | | | |!| | | | | | | | | | |H01| | | |H02|H01=BP response|H02=No BP response}}
{{familytree | | | | | | |!| | | | | | | | | | | |!| | | | | |!|}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | |!| | | | | |!|}}
{{familytree | | | | | |I01| | | | | | | | | |I02| | | |I03|I01=Subtype classification|I02=• Deoxycorticosterone excess( Tumor, 17 alpha hydroxylase and 11 beta hydroxylase deficiency)<br>• Licorice ingestion<br>•Glucocorticoid resistance|I03=Liddle's syndrome)|}}
{{familytree | | | | | | | | |I01| | | | | | | | | |I02| | | |I03|I01=Subtype classification|I02=• Deoxycorticosterone excess( Tumor, 17 alpha hydroxylase and 11 beta hydroxylase deficiency)<br>• Licorice ingestion<br>•Glucocorticoid resistance|I03=Liddle's syndrome)|}}
{{familytree | | | | | |J01| | | | | | | | | | | | | | | | | |J01=Adrenal CT scan}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | |J01| | | | | | | | | | | | | | | | | |J01=Adrenal CT scan}}
{{familytree | | | |,|-|-|-|-|-|^|-|-|-|.|}}
{{familytree | | | |K01| | | | | |K02|K01= Normal, micornodularity, bilateral masses or unilateral atypical mass|K02= Unilateral hypodense nodule >1cm and <2cm in the setting of marked primary hyperaldosteronism|}}
{{familytree | |,|-|^|-|.| | | | |,|-|^|-|-|-|.}}
{{familytree|L01| |L02| | |L03| | | |L04|L01= Surgery not desired|L02=Surgery desired|L03= Surgery desired|L04=Surgery not desired|}}
{{familytree | |!| | | |!| | |,|-|^|-|.| | | |!| | | |}}
{{familytree | |!| | | |!| | |M01| |M02| |!| | | | |M01= > 35 years consider|M02= < 35 years consider|}}
{{familytree | |!| | | |!| | |!| | | |!| | | |!| | | |}}
{{familytree |N01| | |N02|N03| |N04| |N05| | | |N01=• Glucocorticoid-remediable aldosteronism (GRA)<br> •Idiopathic hyperaldosteronism|N02= Adrenal Venous Sampling|N03= Adrenal Venous Sampling|N04=Aldosterone Producing Adenoma (APA) or Primary Adrenal Hyperplasia (PAH):<br> Unilateral laproscopic adrenalectomy|N05= Pharmacological therapy|}}

Revision as of 21:07, 17 July 2017

Template:Primary hyperladosteronism Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Causes

Common Causes

Common causes of Conn's Syndrome may be divided into:

  • Adrenal causes:
    • Aldosterone-secreting adrenal adenoma (APA-benign tumor, 50-60%)
    • Idiopathic hyperaldosteronism (IHA-Bilateral hyperplasia of the adrenal gland, 40-50%)
  • Extra-adrenal causes
    • Ectopic secretion of aldosterone (Ovaries and Kidneys)

Less Common Causes

  • Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism [GRA])
  • Familial hyperaldosteronism II (the familial occurrence of APA or bilateral idiopathic hyperplasia or both)
  • Familial hyperaldosteronism type III (associated with the germline mutation in the KCNJ5 potassium channel)
  • Pure aldosterone-producing adrenocortical carcinomas
  • Unilateral adrenal hyperplasia

Diagnosis and Treatment

 
 
 
 
 
 
 
 
 
 
 
Preferred screening population:

• Blood pressure > 160 / 100 particularly (< 50 years)
• Resistant hypertension or refractory hypertension (use of > 3 anti-hypertensives and poor control of blood pressure)
• Hypokalemia (provoked by diuretic therapy or unprovoked)
• Hypertension and incidentally discovered adrenal adenoma
• Hypertension with a family history of early-onset hypertension (< 20 years) or cerebrovascular accident at age less than 40 years

• Hypertensive first-degree relatives of patients with PA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma Renin Activity/Aldosterone Ratio
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal or High Renin (Plasma Renin/Aldosterone ratio <10
 
 
 
 
 
 
 
 
 
 
 
Suppressed Renin (Plasma Renin/Aldosterone ratio >20
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•Renin-secreting tumors
•Diuretic use
•Renovascular hypertension
•Coarctation of aorta
•Malignant phase hypertension
 
 
 
 
 
 
 
 
 
 
 
Urinary aldosterone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Elevated
 
 
 
 
 
 
 
Normal
 
 
Low
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conn's syndrome (Primary aldosteronism)
 
 
 
 
 
 
 
Profound K+ depletion
 
 
• 17 alpha hydroxylase deficiency
• 11 beta hydroxylase deficiency
• Liddle's syndrome
• Licorice ingestion
•Deoxycorticosterone producing tumor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Do confirmatory tests:
•Fludrocortisone supression test (Positive test= Aldosterone > 6 ng / dl and simultaneous PRA levels < than 1.0 ng / ml / hour)
OR
•Intravenous saline load testing (Positive test= Aldosterone more than 10 ng / dl)
OR
•Oral sodium loading test (Positive test= 24-hour urinary aldosterone excretion > 12 μg / day
OR
•Captopril challenge test (Positive test= PAC / PRA > 30, measured two hours after the administration of 25 mg or 50 mg of captopril)
 
 
 
 
 
 
 
 
 
 
 
 
Add Mineralocrticoid antagonist for 8 weeks
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BP response
 
 
 
No BP response
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subtype classification
 
 
 
 
 
 
 
 
 
• Deoxycorticosterone excess( Tumor, 17 alpha hydroxylase and 11 beta hydroxylase deficiency)
• Licorice ingestion
•Glucocorticoid resistance
 
 
 
Liddle's syndrome)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adrenal CT scan
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal, micornodularity, bilateral masses or unilateral atypical mass
 
 
 
 
 
Unilateral hypodense nodule >1cm and <2cm in the setting of marked primary hyperaldosteronism
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgery not desired
 
Surgery desired
 
 
Surgery desired
 
 
 
Surgery not desired
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
> 35 years consider
 
< 35 years consider
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Glucocorticoid-remediable aldosteronism (GRA)
•Idiopathic hyperaldosteronism
 
 
Adrenal Venous SamplingAdrenal Venous Sampling
 
Aldosterone Producing Adenoma (APA) or Primary Adrenal Hyperplasia (PAH):
Unilateral laproscopic adrenalectomy
 
Pharmacological therapy